Figure 2.
The prevalence of predicted human immunodeficiency virus 1 drug resistance mutations in different drug classes among individuals experiencing virological failure to first-line antiretroviral treatment in Henan, China during 2010–2011. N+NN+ the existence of both nucleoside reverse transcriptase inhibitor (NRTI) and non-(N)NRTI resistance mutation, N+NN− the existence of NRTI but not NNRTI resistance mutations, N-NN+ the existence of NNRTI but not NRTI resistance mutations.